Kangxino Bio opened low, led Hong Kong stock medical care, Hang Seng Medical ETF (513060) severing premium

This morning, the Hang Seng Medical Health Care Index opened low and fell 2.77%.Among the ingredients stocks, Kangshino Bio, Hansen Pharmaceuticals led the decline, Rongchang Bio, Cinda Bio fell more than 6%, minimally invasive robots, and Huang Pharmaceuticals fell, Yasheng Pharmaceuticals, Chinese Medicine Holdings, and Ding Ding Pharmaceuticals led the rise.Hang Seng Medical ETF (513060) fell 1.28%, with a premium of 0.37%in the market. The multi -headed mood was strong, and the turnover exceeded 200 million yuan.

Kangshino announced on the 26th that the company's total operating income in the first half of the year was about 630 million yuan, a year -on -year decrease of 69.45%; the business loss was 165 million yuan, and the profit of 802 million yuan in the same period last year; the total profit and comprehensive income during the period was 16.043 million yuan, a year -on -year decrease of decline98.29%.

CITIC Construction Investment said that the first half of the year of Kangsino was commercialized.In the first half of the year, the MCV2 has completed the market access of nearly 20 provinces and cities in China. MCV4 was issued for the first time in June 2022. It is expected that the situation will be relieved in the second half of the year.Drive the company's vaccine product performance growth.

- END -